In early February, my Development colleagues and I attended an event at a private home in Palm Springs. The program included remarks by President Benson, Chancellor Distefano and me. The keynote speaker was Leslie Leinwand of CU Boulder's Colorado Initiative in Molecular Biotechnology (CIMB). When introducing me, the chancellor mentioned that the Boulder Campus "needs a strong Business School," a remark that pleased all of our alumni at the event.
In my remarks, I emphasized the need for collaboration with other academic units including CIMB. Collaboration has always been part of our culture. We currently offer dual MBA degrees with Law, Anthropology, Computer Science, Environmental Studies, Fine Arts, Germanic and Slavic Languages, Telecommunications and Theater. Entrepreneurship certificates in collaboration with the College of Engineering and the School of Music are also in place and we are in the process of establishing a partnership with the School of Journalism.
The Colorado Initiative in Molecular Biotechnology represents a very exciting opportunity for collaboration. CU's commitment to this initiative is largely responsible for attracting Nobel Laureate Prof. Tom Cech back to the Boulder Campus. The CIMB vision is to formulate a new model "for discovery, development, and commercialization of therapies to address world-wide health issues." As such, the "Leeds School of Business will be a critical partner in the CIMB program by helping to build new programs for entrepreneurs that are prepared to lead in the global, competitive, and complex bioscience industry". Our goal is to establish programs that would include courses such as UC Berkeley's "Entrepreneurship in Biotechnology", which are designed for both those who would like to commercialize research outcomes (i.e., the entrepreneurs) and those who may someday work in startup companies in the biotechnology or medical device space. The collaboration is powerful because "not only will science students be welcome, but business students who are learning how to transfer technologies into the marketplace will be an essential part of the new education paradigm".
The most compelling argument for the CIMB/Leeds partnership is best stated by Damian Hine and John Kapeleris in Innovation and Entrepreneurship in Biotechnology, An International Perspective: Concepts, Theories and Cases: "biotechnology is at a crossroads; to date the science has been solid, yet commercial success remains elusive, and that it will be ... commercial success ... which will dictate the long term viability of this crucial industry." The Leeds school is proud and excited to work with our partners in CIMB to help bring the commercial possibilities of biotechnology to fruition.
To that end and in the larger realm of collaboration, I ask my readers: In what other partnerships would you like to see Leeds school involvement?
In my remarks, I emphasized the need for collaboration with other academic units including CIMB. Collaboration has always been part of our culture. We currently offer dual MBA degrees with Law, Anthropology, Computer Science, Environmental Studies, Fine Arts, Germanic and Slavic Languages, Telecommunications and Theater. Entrepreneurship certificates in collaboration with the College of Engineering and the School of Music are also in place and we are in the process of establishing a partnership with the School of Journalism.
The Colorado Initiative in Molecular Biotechnology represents a very exciting opportunity for collaboration. CU's commitment to this initiative is largely responsible for attracting Nobel Laureate Prof. Tom Cech back to the Boulder Campus. The CIMB vision is to formulate a new model "for discovery, development, and commercialization of therapies to address world-wide health issues." As such, the "Leeds School of Business will be a critical partner in the CIMB program by helping to build new programs for entrepreneurs that are prepared to lead in the global, competitive, and complex bioscience industry". Our goal is to establish programs that would include courses such as UC Berkeley's "Entrepreneurship in Biotechnology", which are designed for both those who would like to commercialize research outcomes (i.e., the entrepreneurs) and those who may someday work in startup companies in the biotechnology or medical device space. The collaboration is powerful because "not only will science students be welcome, but business students who are learning how to transfer technologies into the marketplace will be an essential part of the new education paradigm".
The most compelling argument for the CIMB/Leeds partnership is best stated by Damian Hine and John Kapeleris in Innovation and Entrepreneurship in Biotechnology, An International Perspective: Concepts, Theories and Cases: "biotechnology is at a crossroads; to date the science has been solid, yet commercial success remains elusive, and that it will be ... commercial success ... which will dictate the long term viability of this crucial industry." The Leeds school is proud and excited to work with our partners in CIMB to help bring the commercial possibilities of biotechnology to fruition.
To that end and in the larger realm of collaboration, I ask my readers: In what other partnerships would you like to see Leeds school involvement?
